FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1830603669> ?p ?o ?g. }

• W1830603669 endingPage "574" @default.
• W1830603669 startingPage "S" @default.
• W1830603669 abstract "Background: To reduce the risk of upper gastrointestinal (UGI) complications related to non-steroidal anti-inflammatory drugs (NSAIDs), gastroprotective strategies (GPS) are recommended in patients at risk. Aim: To compare GPS prescription behaviour by general practitioners (GP) in 3 European countries. Methods: We conducted a population-based cohort study in 3 GP databases: 1) United Kingdom's (UK) GP Research Database (1998-2008), 2) Italy's (IT) Health Search/Thales Database (2000-2007), and 3) the Dutch (NL) Integrated Primary Care Information database (1996-2006). Study cohorts comprised all incident NSAID users ≥50 yrs. As preventive strategies we considered: 1) co-prescription of proton pump inhibitors, double dose H2-receptor antagonists, or misoprostol, or 2) use of a cyclooxygenase-2-specific inhibitor (coxib). Consistent with American College of Gastroenterology treatment guidelines, appropriate prescription was defined as the use of a GPS in NSAID users with≥1 UGI risk factor (history of UGI bleeding/ulceration, age≥ 65 yrs, concomitant use of anticoagulants, aspirin, or corticosteroids) and also no GPS in patients without UGI risk factors. Under-prescription was defined as no GPS in patients with ≥1 UGI risk factor. Over-prescription was the presence of a GPS in patients with no UGI risk factors. Results: The study populations comprised of 384,649 UK (mean age: 64.8 yrs, 41% male), 179,030 IT (mean age: 64.6 yrs, 41.7% male) and 55,005 NL NSAID users (mean age: 63.4 yrs, 42.6% male). In the UK, appropriate prescription increased from 51% in 1998 to 59% in 2008 (linear trend (lt) p<0.001) and over-prescription from 3% to 7% (lt p=0.04). Underprescription fell from 46% to 34% (lt p<0.001). In IT, appropriate prescription rose from 46% in 2000 to 60% in 2007 (lt p<0.001) and over-prescription from 3% to 8% (lt p= 0.74), while under-prescription fell from 51% to 32% (lt p=0.01). In the NL, appropriate prescription rose from 53% in 1996 to 63% in 2006 (lt p<0.001) and over-prescription from 4% to 14% (lt p<0.001). Under-prescription decreased from 43% to 23% (lt p<0.001). Between 2000 and 2006, appropriate prescription was significantly higher and underprescription significantly lower in NL compared to UK and IT (p<0.001). Conclusions: The appropriate prescription of GPS has increased over the past years in all three countries assessed. Although under-prescription of GPS use has decreased, it still occurred in 23-34% of NSAID users with upper GI risk factors. This still requires major improvement. The variability across countries was smaller than expected, considering the cultural and structural differences between national health care systems. However, differences across countries are likely to influence the incidence of NSAID-related UGI complications and health care costs." @default.
• W1830603669 created "2016-06-24" @default.
• W1830603669 creator A5007345041 @default.
• W1830603669 creator A5011711127 @default.
• W1830603669 creator A5020080817 @default.
• W1830603669 creator A5036713064 @default.
• W1830603669 creator A5041523142 @default.
• W1830603669 creator A5052413250 @default.
• W1830603669 creator A5061279178 @default.
• W1830603669 creator A5081503066 @default.
• W1830603669 date "2011-05-01" @default.
• W1830603669 modified "2023-09-27" @default.
• W1830603669 title "Time-Trends in Use of Gastroprotective Strategies With NSAID Treatment in the United Kingdom, Italy, and the Netherlands; A Comparative Study" @default.
• W1830603669 doi "https://doi.org/10.1016/s0016-5085(11)62377-9" @default.
• W1830603669 hasPublicationYear "2011" @default.
• W1830603669 type Work @default.
• W1830603669 sameAs 1830603669 @default.
• W1830603669 citedByCount "1" @default.
• W1830603669 crossrefType "journal-article" @default.
• W1830603669 hasAuthorship W1830603669A5007345041 @default.
• W1830603669 hasAuthorship W1830603669A5011711127 @default.
• W1830603669 hasAuthorship W1830603669A5020080817 @default.
• W1830603669 hasAuthorship W1830603669A5036713064 @default.
• W1830603669 hasAuthorship W1830603669A5041523142 @default.
• W1830603669 hasAuthorship W1830603669A5052413250 @default.
• W1830603669 hasAuthorship W1830603669A5061279178 @default.
• W1830603669 hasAuthorship W1830603669A5081503066 @default.
• W1830603669 hasBestOaLocation W18306036691 @default.
• W1830603669 hasConcept C13801280 @default.
• W1830603669 hasConcept C151730666 @default.
• W1830603669 hasConcept C71924100 @default.
• W1830603669 hasConcept C86803240 @default.
• W1830603669 hasConcept C99454951 @default.
• W1830603669 hasConceptScore W1830603669C13801280 @default.
• W1830603669 hasConceptScore W1830603669C151730666 @default.
• W1830603669 hasConceptScore W1830603669C71924100 @default.
• W1830603669 hasConceptScore W1830603669C86803240 @default.
• W1830603669 hasConceptScore W1830603669C99454951 @default.
• W1830603669 hasIssue "5" @default.
• W1830603669 hasLocation W18306036691 @default.
• W1830603669 hasOpenAccess W1830603669 @default.
• W1830603669 hasPrimaryLocation W18306036691 @default.
• W1830603669 hasRelatedWork W1506200166 @default.
• W1830603669 hasRelatedWork W1995515455 @default.
• W1830603669 hasRelatedWork W2039318446 @default.
• W1830603669 hasRelatedWork W2048182022 @default.
• W1830603669 hasRelatedWork W2080531066 @default.
• W1830603669 hasRelatedWork W2604872355 @default.
• W1830603669 hasRelatedWork W2748952813 @default.
• W1830603669 hasRelatedWork W2899084033 @default.
• W1830603669 hasRelatedWork W3032375762 @default.
• W1830603669 hasRelatedWork W3108674512 @default.
• W1830603669 hasVolume "140" @default.
• W1830603669 isParatext "false" @default.
• W1830603669 isRetracted "false" @default.
• W1830603669 magId "1830603669" @default.
• W1830603669 workType "article" @default.